MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.psychres.2026.117419

Медицинская библиотека · Psychiatry research · 2026

Real-world effectiveness and tolerability of desvenlafaxine in major depressive disorder: A multicentre prospective Italian national-cohort study.

d'Andrea Giacomo, Cavallotto Clara, Allegretti Rita, Lupi Matteo, Carmassi Claudia, Ventriglio Antonio, Quattrone Diego, Zanardi Raffaella, Barlati Stefano, Martiadis Vassilis, Ricci Valerio, Nicola Marco Di, Andriola Ileana, Chiappini Stefania, Benatti Beatrice, Barra Andrea, De Berardis Domenico, Signorelli Maria Salvina, Lorenzo Giorgio Di, Bellomo Antonello, Dell'Osso Bernardo Maria, Vita Antonio, Maina Giuseppe, Pettorruso Mauro, Martinotti Giovanni, REMEDY-MDD Study Group, D'Attilio Antonio, Mammarella Giovanna, Persico Luca, Santeusanio Alessia, Panichella Serena, D'angola Michela, Rosati Arianna, Tamagnini Gianfranco, Carano Alessandro, Pedrinelli Virginia, Dell'Oste Valerio, Lumetta Valeria, Carminati Matteo, Raffone Fabiola, Pepe Maria, Cuccia Federica, Rodolico Alessandro

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Real-world evidence on desvenlafaxine effectiveness and tolerability in Major Depressive Disorder (MDD) remains limited, particularly in clinically heterogeneous populations. This multicentre observational study evaluated the real-world effectiveness and tolerability of desvenlafaxine, focusing on depressive and anxiety symptoms, response, remission, and side-effects burden.

METHODS

This multicentre prospective observational study included 197 outpatients with DSM-5-TR Major Depressive Episode initiating desvenlafaxine. Assessments were conducted at baseline (T0), one month (T1), and three months (T2). Depressive symptoms (MADRS) were the primary outcome; anxiety (HAM-A), manic symptoms (YMRS), and tolerability (ASEC) were secondary outcomes. Response was defined as ≥50% MADRS reduction and remission as MADRS <10.

RESULTS

Participants (mean age 46.1 ± 14.6 years; 55.3% female) showed clinically relevant baseline severity (MADRS 30.8 ± 7.3). MADRS scores decreased significantly over time in both unadjusted and adjusted models (both p < 0.005), with greater reductions at T2. A significant time × dose association was observed at T1 (p = 0.013), although no dose-related difference persisted at T2; prior hospitalisation was associated with attenuated improvement (p < 0.005). Anxiety symptoms improved significantly across follow-up (p < 0.005). Response and remission rates increased markedly from T1 to T2 (response: 12.4% to 66.7%; remission: 3.9% to 32.6%; both p < 0.005). Overall side-effect burden decreased significantly (p < 0.005), with reduced prevalence of most adverse events. Mean YMRS scores remained low throughout follow-up, with no clinically meaningful increase from baseline.

CONCLUSIONS

In this multicentre real-world cohort, desvenlafaxine was associated with substantial improvements in depressive and anxiety symptoms, increasing response and remission rates, favourable tolerability. These findings support desvenlafaxine as an effective and well-tolerated treatment option in routine clinical practice.

Для цитирования: d'Andrea Giacomo, Cavallotto Clara, Allegretti Rita, Lupi Matteo, Carmassi Claudia, Ventriglio Antonio, Quattrone Diego, Zanardi Raffaella, Barlati Stefano, Martiadis Vassilis, Ricci Valerio, Nicola Marco Di, Andriola Ileana, Chiappini Stefania, Benatti Beatrice, Barra Andrea, De Berardis Domenico, Signorelli Maria Salvina, Lorenzo Giorgio Di, Bellomo Antonello, Dell'Osso Bernardo Maria, Vita Antonio, Maina Giuseppe, Pettorruso Mauro, Martinotti Giovanni, REMEDY-MDD Study Group, D'Attilio Antonio, Mammarella Giovanna, Persico Luca, Santeusanio Alessia, Panichella Serena, D'angola Michela, Rosati Arianna, Tamagnini Gianfranco, Carano Alessandro, Pedrinelli Virginia, Dell'Oste Valerio, Lumetta Valeria, Carminati Matteo, Raffone Fabiola, Pepe Maria, Cuccia Federica, Rodolico Alessandro. Real-world effectiveness and tolerability of desvenlafaxine in major depressive disorder: A multicentre prospective Italian national-cohort study.. Psychiatry research. 2026. DOI: 10.1016/j.psychres.2026.117419.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.